Johnson & Johnson seeks FDA approval for Caplyta in bipolar mania
Johnson & Johnson has asked the FDA to approve Caplyta (lumateperone) for manic or mixed episodes associated with bipolar I disorder in adults. The supplemental application is supported by two Phase 3 trials in which once-daily treatment significantly reduced mania symptoms compared with placebo, with improvement evident by Day 3 and sustained through Week 3; both studies also met their primary and key secondary endpoints. The company reported that the drug was generally well tolerated, with low discontinuation rates and a safety profile consistent with earlier studies. Caplyta is already approved for schizophrenia, bipolar depression and, as an add-on to antidepressants, major depressive disorder; if the FDA approves the new use, it would be the drug’s fifth approved adult indication.
How it spread




